VasoMedical to Exhibit Proprietary Products at MEDICAL FAIR ASIA 2014 in Singapore

WESTBURY, N.Y. – August 15, 2014VasoMedical, Inc. (“VasoMedical”) (“the Company”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of External CounterPulsation therapy, and patient monitoring products, announced today that it will exhibit at MEDICAL FAIR ASIA 2014 from September 9 -11, 2014 in Suntec, Singapore.

The healthcare market in the Asia Pacific region is expanding rapidly. In 2012 it was worth $369.9 billion, and is expected to reach $752 billion by 2018. MEDICAL FAIR ASIA 2014 marks the 10th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical &; Rehabilitation Equipment & Supplies. The event is Asia's top meeting for the medical and healthcare industries and has become the leading and most established trade fair focused on medical equipment and supplies for this region. The event has received growing support and official endorsement from the medical and healthcare sectors.

VasoMedical's exhibition will be located at Booth 4M21 at the Suntec International Convention and Exhibition Centre.

The Company will showcase its BIOXTM products including MobiCareTM and EECP® Therapy systems. The MobiCareTM Patient Monitor is a multi-parameter patient monitor that wirelessly transmits the patient's vital signs, including ECG, respiration, SpO2, temperature and NIBP, to a bedside receiver or tablet display, from which the information can be further relayed for remote viewing and analysis.

“We look forward to exhibiting our products at the MEDICAL FAIR ASIA 2014, as this event provides us with the ideal forum to introduce new products and increase awareness of our BIOX patient monitoring and EECP Therapy products in this rapidly growing market,” stated Larry Liebman, Vice President of Sales & Marketing at VasoMedical Solutions, Inc.

“As a leading medical technology company, VasoMedical, with operating subsidiaries in the United States and China, continues to look for ways to increase recognition of its innovative products in the broader Asian market, which is heavily focused on meeting the needs of its burgeoning healthcare industry. This growth, driven by the graying market in Asia, is expected to increase the demand for quality healthcare products and services at reduced prices, incorporating the latest technologies in signal acquisition, processing and communications.  With an expected CAGR of 15.1% the Asia-Pacific region is forecasted to become one of the fastest growing markets globally. Given this strong demand, we are looking forward to showcasing our products and further penetrating this fast-paced healthcare market,” concluded Mr. Liebman.

About VasoMedical

VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: VasoMedical Solutions, Inc., VasoMedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support.. Additional information is available on the Company's website at

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Michael J. Beecher/Amanda Jiang
Investor Relations
Phone: 212-508-5840
Email: /

Home | Back to News

©2017 Vaso Corporation